menu

Practicing Precision in ALK and ROS1 Rearrangement Positive NSCLC: Testing, Targets, and Treatments

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Practicing Precision in ALK and ROS1 Rearrangement Positive NSCLC: Testing, Targets, and Treatments

close
1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.

    The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated. 

    This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Evaluate the evolving science and guideline recommendations for molecular testing in NSCLC, including testing for ALK and ROS1 rearrangements.
    2. Apply appropriate treatment selection of ALK and ROS1 targeted agents based upon efficacy data, recommended guidelines, and biomarker testing results to improve patient outcomes.
    3. Implement strategies to incorporate best practices for molecular testing, and biomarker-guided personalized treatment decision-making, and sequencing across the continuum of NSCLC care.
    4. Identify factors that act as barriers or challenges to appropriate use of biomarker testing and strategies to address and optimize treatment outcomes for patients with NSCLC who harbor actionable mutations.
  • Target Audience

    This activity is intended for medical oncologists, thoracic oncologists, surgeons, pathologists, pulmonologists, oncology advanced practitioners (nurses, physician assistants, pharmacists), laboratory professionals, genetic counselors, and other healthcare professionals involved in the treatment of NSCLC.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Maria E. Arcila, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co, AstraZeneca Pharmaceuticals LP, and Janssen Oncology. Serve(d) as a speaker or a member of a speakers bureau for: Biocartis and Invivoscribe. Alexander Drilon, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Roche/Genentech/Ignyta; Loxo/Bayer/Lilly; Takeda Oncology/Ariad/Millenium; Turning Point Therapeutics, Inc; AstraZeneca Pharmaceuticals LP; Pfizer, Inc; Blueprint Medicines; Helsinn Therapeutics (US) Inc; BeiGene LTD; BerGenBio; Hengrui Therapeutics, Inc; Exelixis, Inc; Tyra Biosciences; Verastem Inc; MORE Health; and AbbVie. Research grant: Foundation Medicine. Research support to Memorial Sloan Kettering Cancer Center: Pfizer, Inc; Exelixis, Inc; GlaxoSmithKline; Teva Pharmaceuticals; Taiho Pharmaceutical Co, Ltd; and Pharma Mar, S.A. Royalty: Wolters Kluwer. Other, Food and Beverage: Merck & Co, Inc and PUMA Biotechnology.

    The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive  1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 8/24/2022 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for for 1.0  contact hour of continuing pharmacy education credit JA4008106-0000-21-082-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:         
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.

    The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated. 

    This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Evaluate the evolving science and guideline recommendations for molecular testing in NSCLC, including testing for ALK and ROS1 rearrangements.
    2. Apply appropriate treatment selection of ALK and ROS1 targeted agents based upon efficacy data, recommended guidelines, and biomarker testing results to improve patient outcomes.
    3. Implement strategies to incorporate best practices for molecular testing, and biomarker-guided personalized treatment decision-making, and sequencing across the continuum of NSCLC care.
    4. Identify factors that act as barriers or challenges to appropriate use of biomarker testing and strategies to address and optimize treatment outcomes for patients with NSCLC who harbor actionable mutations.
  • Target Audience

    This activity is intended for medical oncologists, thoracic oncologists, surgeons, pathologists, pulmonologists, oncology advanced practitioners (nurses, physician assistants, pharmacists), laboratory professionals, genetic counselors, and other healthcare professionals involved in the treatment of NSCLC.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Maria E. Arcila, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co, AstraZeneca Pharmaceuticals LP, and Janssen Oncology. Serve(d) as a speaker or a member of a speakers bureau for: Biocartis and Invivoscribe. Alexander Drilon, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Roche/Genentech/Ignyta; Loxo/Bayer/Lilly; Takeda Oncology/Ariad/Millenium; Turning Point Therapeutics, Inc; AstraZeneca Pharmaceuticals LP; Pfizer, Inc; Blueprint Medicines; Helsinn Therapeutics (US) Inc; BeiGene LTD; BerGenBio; Hengrui Therapeutics, Inc; Exelixis, Inc; Tyra Biosciences; Verastem Inc; MORE Health; and AbbVie. Research grant: Foundation Medicine. Research support to Memorial Sloan Kettering Cancer Center: Pfizer, Inc; Exelixis, Inc; GlaxoSmithKline; Teva Pharmaceuticals; Taiho Pharmaceutical Co, Ltd; and Pharma Mar, S.A. Royalty: Wolters Kluwer. Other, Food and Beverage: Merck & Co, Inc and PUMA Biotechnology.

    The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive  1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 8/24/2022 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for for 1.0  contact hour of continuing pharmacy education credit JA4008106-0000-21-082-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:         
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/25/21